• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

IBM partners to identify risk factors for Type I diabetes

August 18, 2017 By Sarah Faulkner

IBMIBM (NYSE:IBM) plans to develop and apply machine learning techniques to years of research data in the hopes of identifying factors that trigger the onset of Type I diabetes in children, with the support of JDRF.

Scientists at IBM are slated to assess three different data sets using machine learning algorithms to find patterns and factors that could one day help delay or prevent Type I diabetes.

“At JDRF, we are absolutely committed to seeing a world without Type I diabetes, and with this partnership, we’re adding some of the most advanced computing power in the world to our mission,” JDRF president & CEO Derek Rapp said in prepared remarks. “JDRF supports researchers all over the world, but never before have we been able to analyze their data comprehensively, in a way that can tell us why some children who are at risk get T1D and others do not. IBM’s analysis of the existing data could open the door to understanding the risk factors of T1D in a whole new way, and to one day finding a way to prevent T1D altogether.”

The group may eventually incorporate more complex data sets, they said, including microbiome and genomics data.

“Nearly 40,000 new cases of Type I diabetes will be diagnosed in the U.S. this year. And each new patient creates new records and new data points that, if leveraged, could provide additional understanding of the disease,” Jianying Hu, senior manager and program director at the Center for Computational Health, added. “The deep expertise our team has in artificial intelligence applied to healthcare data makes us uniquely positioned to help JDRF unlock the insights hidden in this massive data set and advance the field of precision medicine towards the prevention and management of diabetes.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2.

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: IBM, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS